摘要
目的观察聚乙二醇干扰素α-2a联合利巴韦林治疗老年慢性丙型肝炎患者的抗病毒治疗的应答情况及安全性。方法回顾性分析68例慢性丙型肝炎基因1型患者,分为老年组(≥55岁)36例,中青年组(年龄<55岁)32例,均给予聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗,观察病毒学应答、生化学应答及不良反应情况。结果两组患者治疗结束时病毒学应答(ETVR)、病毒学持续应答(SVR)及生化学应答相比差异无统计学意义(P<0.05),而不良反应中,老年组在焦虑、抑郁、中性粒细胞及血小板下降发生率均高于中青年组,差异均具有统计学意义(P<0.05)。结论老年患者抗病毒治疗虽然不良反应较大,但如果坚持完成治疗,持续病毒学应答率与中青年患者相近。
Objective To observe the efficacy and safety of pegylated interferon -2a and ribavirin in treatment of elderly patients with chronic hepatitis C. Methods The 68 chronic hepatitis C genotype 1 patients were divided into senile group （36 cases≥ 55 years）and the young group （32 cases 〈 55 years）. All the patients in both groups were treated with pegylated interferon plus ribavirin antiviral -2a and the viral response and adverse circumstances were observed and analyzed. Results At the end of treatment, no statistically significant differences were observed in viral response （ETVR）,a sustained viral response （SVR）and biochemical response in between the two groups （P〉0.05）,while the adverse reaction,anxiety,depression,the decrease rates of neutrophil and platelet in the senile group were higher than that of the young group,showing statistically significant differences （P〈0.05）. Conclusions Although the adverse reactions were relative severe in antiviral therapy in senile patients,the viral response would be similar with that of the patients in young group if persisting completion of treatment.
出处
《中国热带医学》
CAS
2013年第8期1013-1014,1017,共3页
China Tropical Medicine
